WO2003105907A3 - Compositions pour le transport de molecules therapeutiques dans les poumons, et leur utilisation pour leur traitement des cancers du poumon et des maladies pulmonaires - Google Patents

Compositions pour le transport de molecules therapeutiques dans les poumons, et leur utilisation pour leur traitement des cancers du poumon et des maladies pulmonaires Download PDF

Info

Publication number
WO2003105907A3
WO2003105907A3 PCT/FR2003/001864 FR0301864W WO03105907A3 WO 2003105907 A3 WO2003105907 A3 WO 2003105907A3 FR 0301864 W FR0301864 W FR 0301864W WO 03105907 A3 WO03105907 A3 WO 03105907A3
Authority
WO
WIPO (PCT)
Prior art keywords
arg
ser
treatment
lung
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/001864
Other languages
English (en)
Other versions
WO2003105907A2 (fr
Inventor
Jamal Temsamani
Anthony R Rees
Christophe Rousselle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt EM SA filed Critical Synt EM SA
Priority to EP03760057A priority Critical patent/EP1513557A2/fr
Priority to CA002488879A priority patent/CA2488879A1/fr
Priority to JP2004512807A priority patent/JP2006517177A/ja
Priority to AU2003258813A priority patent/AU2003258813A1/en
Publication of WO2003105907A2 publication Critical patent/WO2003105907A2/fr
Publication of WO2003105907A3 publication Critical patent/WO2003105907A3/fr
Priority to IL16557404A priority patent/IL165574A0/xx
Priority to US11/016,318 priority patent/US20050159360A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet un composé constitué d'au moins une molécule thérapeutique destinée au traitement des cancers du poumon ou de maladies pulmonaires et d'au moins un peptide vecteur capable d'augmenter la biodisponibilité de ladite molécule au niveau des poumons choisi dans le groupe constitué par Ala-Trp-Ser-Phe-Arg-Val-Ser-Tyr-Arg-Gly-Ile-Ser-Tyr-Arg-Arg-Ser-Arg (SynB4) et Arg-Gly-Gly-Arg-Leu-Ser-Tyr-Ser-Cit-Cit-Cit-Phe-Ser-Thr-Ser-Thr-Gly-Arg (SynB6). L'invention concerne aussi les compositions pharmaceutiques contenant ces composés, utiles pour le traitement des cancers du poumon ou des maladies pulmonaires.
PCT/FR2003/001864 2002-06-18 2003-06-18 Compositions pour le transport de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires Ceased WO2003105907A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP03760057A EP1513557A2 (fr) 2002-06-18 2003-06-18 Compositions pour le transport de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
CA002488879A CA2488879A1 (fr) 2002-06-18 2003-06-18 Compositions pour le transport de molecules therapeutiques dans les poumons, et leur utilisation pour leur traitement des cancers du poumon et des maladies pulmonaires
JP2004512807A JP2006517177A (ja) 2002-06-18 2003-06-18 肺へ治療分子を輸送する組成物、並びに肺がん及び肺疾患治療のためのその使用
AU2003258813A AU2003258813A1 (en) 2002-06-18 2003-06-18 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
IL16557404A IL165574A0 (en) 2002-06-18 2004-12-06 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
US11/016,318 US20050159360A1 (en) 2002-06-18 2004-12-17 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/07493 2002-06-18
FR0207493A FR2840810B1 (fr) 2002-06-18 2002-06-18 Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/016,318 Continuation US20050159360A1 (en) 2002-06-18 2004-12-17 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases

Publications (2)

Publication Number Publication Date
WO2003105907A2 WO2003105907A2 (fr) 2003-12-24
WO2003105907A3 true WO2003105907A3 (fr) 2004-04-22

Family

ID=29595347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/001864 Ceased WO2003105907A2 (fr) 2002-06-18 2003-06-18 Compositions pour le transport de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires

Country Status (8)

Country Link
US (1) US20050159360A1 (fr)
EP (1) EP1513557A2 (fr)
JP (1) JP2006517177A (fr)
AU (1) AU2003258813A1 (fr)
CA (1) CA2488879A1 (fr)
FR (1) FR2840810B1 (fr)
IL (1) IL165574A0 (fr)
WO (1) WO2003105907A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
EP2896400A1 (fr) 2014-01-17 2015-07-22 Université Catholique De Louvain Procédé pour augmenter la biodisponibilité de composés inhalés

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007728A2 (fr) * 1997-08-12 1999-02-18 Synt:Em (S.A.) Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
WO2000032236A1 (fr) * 1998-11-30 2000-06-08 Synt:Em (S.A.) Vecteurs peptidiques de substances a travers la barriere hemato-encephalique
WO2000032237A1 (fr) * 1998-11-30 2000-06-08 Synt:Em (S.A.) Composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide
WO2001013957A2 (fr) * 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
WO2002002595A1 (fr) * 2000-07-03 2002-01-10 Synt:Em S.A. Peptides lineaires amphipathiques et les compositions les contenant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005510484A (ja) * 2001-10-16 2005-04-21 シンテム ソシエテ アノニム 抗原に対する免疫応答を改良するためのペプチドベクターの使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007728A2 (fr) * 1997-08-12 1999-02-18 Synt:Em (S.A.) Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
WO2000032236A1 (fr) * 1998-11-30 2000-06-08 Synt:Em (S.A.) Vecteurs peptidiques de substances a travers la barriere hemato-encephalique
WO2000032237A1 (fr) * 1998-11-30 2000-06-08 Synt:Em (S.A.) Composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide
WO2001013957A2 (fr) * 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
WO2002002595A1 (fr) * 2000-07-03 2002-01-10 Synt:Em S.A. Peptides lineaires amphipathiques et les compositions les contenant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAY FIONA H ET AL: "Induction of antigen-specific CTL responses using antigens conjugated to short peptide vectors.", JOURNAL OF IMMUNOLOGY, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1498 - 1503, XP002259153, ISSN: 0022-1767 (ISSN print) *
IMRAN AHMAD ET AL: "ANTIBODY-TARGETED DELIVERY OF DOXORUBICIN ENTRAPPED IN STERICALLY STABILIZED LIPSOMES CAN ERADICATE LUNG CANCER IN MICE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 53, no. 7, 1 April 1993 (1993-04-01), pages 1484 - 1488, XP000371716, ISSN: 0008-5472 *
ROSELL R ET AL: "SINGLE-AGENT PACLITAXEL BY 3-HOUR INFUSION IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER: LINKS BETWEEN P53 AND K-RAS GENE STATUS AND CHEMOSENSITIVITY", SEMINARS IN ONCOLOGY, BETHESDA, MD, US, vol. 22, no. 6, SUPPL 14, December 1995 (1995-12-01), pages 12 - 18, XP001013161 *
ROUSSELLE C ET AL: "ENHANCED DELIVERY OF DOXURUBICIN INTO THE BRAIN VIA A PEPTIDE-VECTOR-MEDIATED STRATEGY: SATURATION KINETICS AND SPECIFICITY", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 296, no. 1, January 2001 (2001-01-01), pages 124 - 131, XP001041627, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
FR2840810B1 (fr) 2005-02-11
EP1513557A2 (fr) 2005-03-16
CA2488879A1 (fr) 2003-12-24
US20050159360A1 (en) 2005-07-21
JP2006517177A (ja) 2006-07-20
FR2840810A1 (fr) 2003-12-19
AU2003258813A1 (en) 2003-12-31
WO2003105907A2 (fr) 2003-12-24
IL165574A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
MA30063B1 (fr) Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg)
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
ES2522968T3 (es) Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EA200701370A1 (ru) Способы получения стерильных суспензий или лиофилизатов труднорастворимых комплексов основных пептидов (варианты), стерильная суспензия и лиофилизат вышеназванных комплексов, фармацевтическая композиция, набор и лекарственное средство на их основе
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
BR0014679A (pt) 2-tio-3,5-diciano-4-aril-6-aminopiridinas substituìdas e sua aplicação
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
EP1502603A4 (fr) MEDICAMENT CONTENANT UNE COMPOSITION D'ANTICORPS APPROPRIEE AU PATIENT SOUFFRANT DE POLYMORPHISME FC gammma RIIIA
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
PL2157192T3 (pl) Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
TR200102072T2 (tr) İltihap karşıtı maddeler olarak aromatik çok döngülü bileşimler
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
EA200401114A3 (ru) Замещённые гидроксиэтиламины
WO2004020462A1 (fr) Antagoniste de cxcr4 et son utilisation
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
EA200100872A1 (ru) Композиция валдекоксиба
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BR9714523A (pt) Tratamento de nefrite de lúpus com compostos anti-cd40l
ATE422356T1 (de) Pharmazeutische zubereitungen
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
NO20001049L (no) Kondenserte tiofenforbindelser og farmasøytisk anvendelse derav
WO2005030238A1 (fr) Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique
MA31133B1 (fr) Nouveau peptide d'actinomadura namibiensis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 165574

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003258813

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2488879

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004512807

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11016318

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003760057

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003760057

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003760057

Country of ref document: EP